Mahsa Panahishokouh

Mahsa Panahishokouh

Auto-generated profile, based on publicly available information

Mahsa Panahishokouh

Department of Clinical Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2025 in Clinical Medicine Insights: Case Reports
Verified
Journal Article
Open access
AAAbdolamir Atapour
Abdolamir Atapour
MPMahsa Panahishokouh
Mahsa Panahishokouh
MMMahnaz Momenzadeh
Mahnaz Momenzadeh
Statins are a class of drugs that are vital for lowering blood lipid levels and reducing the risk of both primary and secondary cardiovascular diseases. These drugs are generally considered safe; however, some individuals may experience side effects, such as muscle pain, headache, fatigue, myopathy, and gastrointestinal disorders. One of the less frequently reported side effects of statins is visual disturbances. We report the case of a 51-year-old woman who developed persistent headache, blurred vision, and diplopia shortly after initiating Atorvastatin. These visual disturbances recurred when treatment was switched to Rosuvastatin and Lovastatin. Comprehensive neurological evaluation, including brain MRI, was unremarkable. All symptoms resolved completely after permanent discontinuation of statin therapy, indicating a rare but significant statin-associated visual adverse event. Due to the significance of reporting this complication, this study aims to present a case of a patient who experienced visual impairment associated with the use of atorvastatin, rosuvastatin, and, to a lesser extent, lovastatin.

14 September 2021 in Pharmaceutical Sciences
Verified
Journal Article
Open access
MPMahsa Panahishokouh
Mahsa Panahishokouh
NANafiseh Alizadeh
Nafiseh Alizadeh
MDMehrnoush Dianatkhah
Mehrnoush Dianatkhah
MBMina Borran
Mina Borran
BBBehnam Behnoush
Behnam Behnoush
Metronidazole induced anaphylactic shock is an extremely rare drug reaction. We reported a 39-year-old man with severe anaphylactic shock caused by Metronidazole. He denied history of food or drugs allergy. Severe cardiovascular collapse suddenly occurred after receiving intravenous Metronidazole. The patient was successfully managed as a case of anaphylactic shock and finally discharge.

11 May 2026 in Clinical Medicine Insights: Case Reports
Verified
Journal Article
Open access
FSFatemeh Sadeghi
Fatemeh Sadeghi
MMMahnaz Momenzadeh
Mahnaz Momenzadeh
MPMahsa Panahishokouh
Mahsa Panahishokouh
Hypersensitivity reactions to second-generation antipsychotics and mood stabilizers are uncommon and can lead to serious complications. These medicines are generally well tolerated, but there have been reports of unusual allergic reactions, such as hives or itching, associated with these drugs. The patient is a 45-year-old woman who presented with a recurrence of a manic episode of bipolar I disorder and developed skin complications and itching after receiving valproate and levetiracetam. She subsequently experienced severe skin allergic reactions, including hives and itching, after taking various second-generation antipsychotics, including risperidone, aripiprazole, and quetiapine. These allergic reactions occurred shortly after starting the medication and resolved after discontinuing the drug. The purpose of this case report is to highlight the importance of being aware of the possibility of concomitant hypersensitivity with various antipsychotic and anticonvulsant medications, which can affect the diagnosis and treatment of the disease.

17 July 2024 in Iranian Journal of Psychiatry and Behavioral Sciences
Verified
Journal Article
Open access
PDF file
NMNiayesh Mohebbi
Niayesh Mohebbi
MMMahtab Motamed
Mahtab Motamed
MPMahsa Panahishokouh
Mahsa Panahishokouh
Context: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of various psychiatric disorders. While the standard therapeutic dose of fluoxetine is typically 20 - 60 mg per day, slow-release higher doses, such as 90 mg/weekly and more recently 180 mg/weekly, have been explored to assess their potential benefits in certain psychiatric conditions. This mini-review aims to evaluate the evidence regarding the effects, efficacy, and safety profile of fluoxetine at a dosage of 90 mg in psychiatry. Evidence Acquisition: A comprehensive literature search was conducted using electronic databases (PubMed and Embase) to identify relevant studies published until July 2023. Studies investigating the use of fluoxetine at a dosage of 90 mg/week in psychiatric conditions were included. The identified studies were critically appraised for their methodology and quality. Results: Limited research has specifically examined the effects of fluoxetine at a dosage of 90 mg/week in psychiatry. However, some studies have investigated this dosage form and provided insights into its potential efficacy in treating certain psychiatric conditions, such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), premature ejaculation, and premenstrual dysphoric disorder. These studies have shown that compliance with weekly fluoxetine was better than with once-daily dosing. Conclusions: Once-weekly dosing may be effective in psychiatry, improving compliance and enhancing psychological well-being.

16 May 2026 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MSMozhdeh Shahabi
Mozhdeh Shahabi
MPMahsa Panahishokouh
Mahsa Panahishokouh
NMNiayesh Mohebbi
Niayesh Mohebbi

26 April 2025 in Journal of Reports in Pharmaceutical Sciences
Verified
Journal Article
Open access
MPMahsa Panahishokouh
Mahsa Panahishokouh
AKAmir Kasaeian
Amir Kasaeian
SJSaedeh Sadat Jafarrangraz
Saedeh Sadat Jafarrangraz
SAShahideh Amini
Shahideh Amini
Background: Medication non-adherence in cystic fibrosis (CF) can lead to reduced drug efficacy and suboptimal care. Objectives: This study aimed to evaluate adherence to commonly used medications and related factors among children and adolescents with CF. Methods: A research pharmacist assessed drug adherence using the 5-item Medication Adherence Rating Scale (MARS-5) through face-to-face interviews with patients and their parents. Based on the MARS-5 score, patients were categorized as having perfect (≥ 25) or lower (< 25) treatment adherence. Results: A total of 300 patients were included in the study. Between 42.0% and 87.9% of patients were lower-adherent in at least one aspect of their treatment. Among those who received all medications, 86.9% were lower-adherent. Specifically, 42.0% of patients had lower adherence to inhalants, 67.6% to systemic antibiotics, 81.4% to gastrointestinal agents, and 87.9% to nutritional supplements. Factors significantly associated with adherence included the number of drugs for inhalants and systemic antibiotics; the mother’s education level for inhalants, systemic antibiotics, and gastrointestinal agents; and distance from the medical center for inhalants and nutritional supplements (all P < 0.05). Conclusions: Non-adherence to inhalants, systemic antibiotics, gastrointestinal agents, and nutritional supplements is common among children and adolescents with CF. Adherence to one class of medication does not predict adherence to others. A high number of drugs, a low mother’s education level, and a long distance from the medical center decrease the likelihood of perfect adherence to CF medications.